Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
 shares announced by Shareholders Foundation - EconoTimes)
SAN DIEGO, Oct. 25, 2016 -- The Shareholders Foundation, Inc. announces that a deadline is coming up on October 31, 2016 in the lawsuit that was filed for certain investors in shares of American Renal Associates Holdings Inc (NYSE:ARA) over alleged Securities Laws Violations by American Renal Associates Holdings.
The lawsuit seeks to recover damages for certain NYSE:ARA investors.
Investors who purchased shares of American Renal Associates Holdings Inc (NYSE:ARA) have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that American Renal Associates Holdings Inc was engaged in a fraudulent scheme to steer patients away from qualified-for Medicare and Medicaid plans into more expensive Affordable Care Act plans to obtain greater reimbursement for the Company’s dialysis services, that the foregoing scheme was in violation of federal and state laws, and that as a result of the foregoing, American Renal Associates Holdings’ public statements were materially false and misleading at all relevant times.
On August 18, 2016, the Centers for Medicare and Medicaid Services, a federal agency within the U.S. Department of Health and Human Services, announced that it had sent warning letters to all dialysis centers that participate in the federal Medicare program. The Centers for Medicare and Medicaid Services also stated that it is weighing financial penalties on providers found to have directed people eligible for Medicare into Affordable Care Act plans instead—as American Renal is alleged to have done.
Those who purchased American Renal Associates Holdings Inc (NYSE:ARA) shares should contact the Shareholders Foundation, Inc. by e-mail at [email protected] or call +1 (858) 779-1554.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
[email protected]
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
